- Record: found
- Abstract: not found
- Article: not found
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong ,
Qun Wang ,
Wei-Min Mao ,
Song-Tao Xu ,
Lin Wu ,
Yi Shen ,
Yong-Yu Liu ,
Chun Chen ,
Ying Cheng ,
Lin Xu ,
Jun Wang ,
Ke Fei ,
Xiao-Fei Li ,
Jian Li ,
Cheng Huang ,
Zhi-Dong Liu ,
Shun Xu ,
Ke-Neng Chen ,
Shi-Dong Xu ,
Lun-Xu Liu ,
Ping Yu ,
Bu-Hai Wang ,
Hai-Tao Ma ,
Hong-Hong Yan ,
Xue-Ning Yang ,
Qing Zhou ,
Yi-Long Wu ,
Yi-Long Wu ,
Qun Wang ,
Wei-Min Mao ,
Lin Wu ,
Yi Shen ,
Yong-Yu Liu ,
Chun Chen ,
Ying Cheng ,
Lin Xu ,
Jun Wang ,
Ke Fei ,
Xiao-Fei Li ,
Jian Li ,
Cheng Huang ,
Zhi-Dong Liu ,
Shun Xu ,
Ke-Neng Chen ,
Shi-Dong Xu ,
Lun-Xu Liu ,
Ping Yu ,
Bu-Hai Wang ,
Hai-Tao Ma ,
Si-Yu Wang ,
Jian Hu ,
Wei Liu ,
Wei Li ,
Jian-Hua Shi
January 2018
January 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected
stage II-IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data suggest
patients with EGFR-mutant stage IB-IIIA resected NSCLC could benefit from adjuvant
EGFR tyrosine kinase inhibitor treatment. We aimed to compare the efficacy of adjuvant
gefitinib versus vinorelbine plus cisplatin in patients with completely resected EGFR-mutant
stage II-IIIA (N1-N2) NSCLC.